Please login to the form below

Not currently logged in
Email:
Password:

farletuzumab

This page shows the latest farletuzumab news and features for those working in and with pharma, biotech and healthcare.

Late-stage ovarian cancer

Late-stage ovarian cancer

Menarini Biotech's abagovomab and Morphotek/ Eisai's farletuzumab have both had disappointing results in late-stage clinical trials. ... Farletuzumab had also entered global phase III trials, in combination with carboplatin and a taxane, in patients with

Latest news

  • Eisai's farletuzumab fails ovarian cancer trial Eisai's farletuzumab fails ovarian cancer trial

    Farletuzumab has also been tipped as a long-term blockbuster prospect for Eisai, if it could be developed in multiple cancer indications. ... Morphotek remains committed to research to understand the potential role of farletuzumab in ovarian and other

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...
Investing in our People
As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....

Infographics